IL 1RA Mouse

Interleukin-1 Receptor Antagonist (IL-1Ra) is a naturally occurring protein that plays a crucial role in regulating the immune response. It is part of the interleukin-1 (IL-1) family of cytokines, which are involved in the initiation and regulation of inflammatory responses. The recombinant form of IL-1Ra, specifically derived from mice, has been extensively studied for its therapeutic potential in various inflammatory diseases.

IL-1Ra was first discovered in 1984 in the urine and serum of patients with leukemia and in the supernatant of cultured monocytes . The protein was named for its ability to competitively bind to the IL-1 receptor, thereby antagonizing the function of IL-1, a potent pro-inflammatory cytokine.

The recombinant form of IL-1Ra, known as anakinra or Kineret™, was developed to mimic the natural antagonist. This recombinant protein differs from the native IL-1Ra by the addition of an N-terminal methionine . It binds to the IL-1 receptor type I with the same affinity as IL-1β, effectively inhibiting its pro-inflammatory effects.

IL-1Ra functions by binding to the IL-1 receptor without eliciting a signal, thereby blocking the binding of IL-1α and IL-1β. This competitive inhibition prevents the downstream signaling that leads to inflammation and tissue damage. By modulating the IL-1 signaling pathway, IL-1Ra helps to control excessive inflammatory responses that can lead to chronic inflammatory diseases .

Recombinant IL-1Ra has been investigated for its potential in treating various inflammatory conditions. One of the most well-studied applications is in the treatment of rheumatoid arthritis (RA). Clinical trials have demonstrated that anakinra, in combination with methotrexate, significantly reduces the signs and symptoms of RA in patients who have inadequate responses to methotrexate alone . The treatment is generally well-tolerated, with the most common side effect being mild to moderate injection site reactions.

In addition to RA, IL-1Ra has shown promise in treating other inflammatory diseases, including psoriasis, atopic dermatitis, and other skin disorders . Its ability to modulate the immune response makes it a valuable therapeutic agent in conditions where excessive inflammation is a key pathological feature.

Ongoing research continues to explore the potential of IL-1Ra in various disease contexts. Studies are investigating its role in other autoimmune and inflammatory diseases, as well as its potential in combination therapies. The development of new delivery methods and formulations aims to improve the efficacy and patient compliance of IL-1Ra treatments.

In conclusion, the recombinant form of Interleukin-1 Receptor Antagonist (Mouse) represents a significant advancement in the treatment of inflammatory diseases. Its ability to effectively inhibit IL-1 signaling and modulate the immune response holds great promise for future therapeutic applications.